Takaishi, Japan

Yuzo Sakaguchi

This inventor holds 1 USPTO granted patent. Top assignee: Dainippon Pharmaceutical Company, Limited. Active years: 1991.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 1991

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Yuzo Sakaguchi: Innovator in Mycoplasma Contamination Prevention

Introduction

Yuzo Sakaguchi is a notable inventor based in Takaishi, Japan. He has made significant contributions to the field of biotechnology, particularly in the prevention of mycoplasma contamination in cell cultures. His innovative approach has implications for both animal and plant cell cultivation.

Latest Patents

Sakaguchi holds a patent for a method aimed at preventing or eliminating mycoplasma contamination in animal or plant cell cultures. The patent describes a process that involves adding an anti-mycoplasmally effective amount of 5-amino-7-(2-aminomethylmorpholino)-1-cyclopropyl-6, 8-difluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid or its salt to the culture medium. This invention is crucial for ensuring the integrity of cell cultures used in research and development.

Career Highlights

Yuzo Sakaguchi is associated with Dainippon Pharmaceutical Company, Limited, where he has been able to apply his expertise in biotechnology. His work has contributed to advancements in pharmaceutical research and development, particularly in ensuring the quality of biological materials.

Collaborations

Sakaguchi has collaborated with notable colleagues such as Shinichi Nakamura and Shigeki Kashimoto. These collaborations have fostered a productive environment for innovation and have led to significant advancements in their respective fields.

Conclusion

Yuzo Sakaguchi's contributions to the prevention of mycoplasma contamination highlight his role as an important figure in biotechnology. His innovative methods and collaborations continue to influence the field positively.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…